Kcnq4 Protein Potassium Channel Kv7.4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNQ4 encodes the Kv7.4 potassium channel, a member of the KCNQ (KQT-like) family of voltage-gated potassium channels. This channel is prominently expressed in outer hair cells of the inner ear and in various neuronal populations, where it plays crucial roles in maintaining the resting membrane potential and regulating cellular excitability.
| Property |
Value |
| Protein Name |
Potassium voltage-gated channel subfamily Q member 4 |
| Gene Symbol |
KCNQ4 |
| UniProt ID |
P56696 |
| Molecular Weight |
~75 kDa |
| Protein Length |
695 amino acids |
| Chromosomal Location |
1p34.3 |
The KCNQ4 channel has a typical voltage-gated potassium channel architecture:
- Six Transmembrane Segments (S1-S6): S1-S4 form the voltage sensor domain
- Pore Loop: Between S5 and S6, contains the selectivity filter (GYG motif)
- N-terminal Domain: Contains residues important for subunit assembly
- C-terminal Domain: Includes the assembly domain and regulatory sites
- Generates the slowly activating and non-inactivating M-current
- Activates at potentials around -50 to -30 mV
- Provides a brake on neuronal excitability
- Critical for outer hair cell electromotility
- Maintains the positive endocochlear potential
- Essential for auditory transduction
- Modulates neuronal firing patterns
- Controls resting membrane potential
- Affects synaptic integration
- Over 60 mutations cause autosomal dominant progressive hearing loss
- Mutations cause loss-of-function
- Degeneration of outer hair cells
- Altered expression in AD brain tissue
- Contributes to neuronal hyperexcitability
- Calcium dysregulation secondary effects
- Basal ganglia expression
- Modulates dopaminergic neuron function
- Potential therapeutic target
- Depression: M-current modulators as antidepressants
- Anxiety: Anxiolytic potential of KCNQ activators
- Schizophrenia: Genetic associations
| Strategy |
Agent |
Status |
| Retigabine |
Ezogabine |
Approved (withdrawn for epilepsy) |
| Flupirtine |
D-18517 |
Approved (analgesic) |
| Novel Activators |
- |
Clinical development |
The study of Kcnq4 Protein Potassium Channel Kv7.4 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kharkovets T, et al. (2000). KCNQ4 is expressed in the inner ear and CNS. Eur J Neurosci. 12(2):538-548.
- Jentsch TJ (2000). Neuronal KCNQ potassium channels. Nat Rev Neurosci. 1(1):21-30.
- Wang J, et al. (2016). Molecular mechanisms of KCNQ4 mutations in hearing loss. Mol Neurobiol. 53(3):1681-1692.
- Brown DA, et al. (2008). Regulation of M-current. Cell Mol Neurobiol. 28(1):67-78.